[1]汤雅倩,赵明烨,唐文熙.信迪利单抗对比卡瑞利珠单抗一线治疗 晚期非鳞状非小细胞肺癌的经济学评价[J].卫生经济研究,2023,40(2):34-40.
　TANG Yaqian,ZHAO Mingye,TANG Wenxi.Pharmacoeconomic Evaluation of Sintilimab Versus Camrelizumab in the First-Line Treatment of Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer in China[J].Journal Press of Health Economics Research,2023,40(2):34-40.
点击复制

信迪利单抗对比卡瑞利珠单抗一线治疗 晚期非鳞状非小细胞肺癌的经济学评价
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
40
期数:
2023年2期
页码:
34-40
栏目:
经济学评价
出版日期:
2023-02-01

文章信息/Info

Title:
Pharmacoeconomic Evaluation of Sintilimab Versus Camrelizumab in the First-Line Treatment of Patients with Non-Squamous Advanced Non-Small Cell Lung Cancer in China
作者:
汤雅倩1; 赵明烨1; 唐文熙1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
TANG Yaqian;  ZHAO Mingye;  TANG Wenxi
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
非小细胞肺癌; 成本效果分析; 分数多项式模型; 经济学评价
Keywords:
non-small cell lung cancer;  cost-effectiveness analysis;  fractional polynomial model;  economic evaluation
分类号:
R734.2；R19
文献标志码:
A
摘要:
目的：对信迪利单抗联合化疗相比于卡瑞利珠单抗联合化疗治疗晚期非鳞状非小细胞肺癌的经济性展开评价。方法：采用Orient 11及Camel试验数据，基于分数多项式模型构建非恒定风险比例的网状Meta分析；采用分区生存模型进行决策分析；考虑到参数的不确定性，进行单因素敏感性分析与概率敏感性分析，并绘制龙卷风图、成本效果散点图及成本效果可接受曲线。结果：卡瑞利珠单抗组和信迪利单抗组总成本分别为113 656元和147 240元，总效用值分别为1.01和1.60QALY，ICER为56 922，显著低于研究阈值，信迪利单抗组具有明显的成本效果优势。结论：信迪利联合化疗治疗晚期非鳞状非小细胞肺癌相比于卡瑞利珠单抗联合化疗具有经济学优势。
Abstract:
Objective Direct comparisons between immune target inhibitors have been a trend in health care negotiations in recent years, and economic evaluations of traditional comparisons with chemotherapy provide limited evidence. Therefore, this study developed an evaluation of the economics of sintilimab in combination with chemotherapy compared with camrelizumab in combination with chemotherapy for non-squamous advanced non-small cell lung cancer from the perspective of our country's health care system. Methods ORIENT 11 and Camel trial data were used to construct a mesh meta-analysis of non-constant risk ratios based on fractional polynomial models. The partition survival model was used for decision analysis, the incremental cost-effect was used as the economic evaluation index, and the willingness-to-pay threshold was 1-3 times the GDP per capita in 2022. Taking into account the uncertainty of parameters, single-factor sensitivity analysis and probability sensitivity analysis were carried out, and a tornado diagram, cost-effectiveness scattergram, and cost-effectiveness acceptable curve were drawn to show their respective results. Results The results of the base-case analysis showed that the total costs in the camrelizumab and sintilimab groups were 113 656 yuan and 147 240 yuan, respectively, with total utility of 1.01 and 1.60 QALYs, respectively, and an ICER of 56 922, which was significantly below the study threshold, providing a substantial cost-effectiveness advantage. Sensitivity analysis results showed that the basic analysis conclusion was stable, and each variable will not affect the research conclusion when it fluctuates within the upper and lower limits. Conclusion Compared with camrelizumab combined with chemotherapy, sintilimab combined with chemotherapy in the treatment of non-squamous advanced non-small cell lung cancer has economic advantages in China.

参考文献/References:

[1] Sung H,Ferlay J,Siegel R L,et al.Global Cancer Statistics 2020:GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[2] Duma N,Santana-Davila R,Molina JR.Non-Small cell lung cancer:Epidemiology, screening,diagnosis,and treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.
[3] Leighl N B.Treatment paradigms for patients with metastatic non-small-cell lung cancer:first, second,and third-line[J].Curr Oncol,2012,19(Suppl 1):S52-58.
[4] Goldstraw P,Chansky K,Crowley J,et al.The IASLC Lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer[J].J Thorac Oncol,2016,11(1):39-51.
[5] 邵楚楚，王婉莹，任胜祥.CSCO非小细胞肺癌诊疗指南（2021版）解读[J].同济大学学报（医学版），2022，43（1）：1-9.
[6] Galetta D,Cinieri S,Pisconti S,et al.Cisplatin/Pemetrexed followed by maintenance pemetrexed versus Carboplatin/Paclitaxel/Bevacizumab followed by maintenance bevacizumab in advanced nonsquamous lung cancer: the GOIM (gruppo oncologico Italia meridionale) ERACLE phase III randomized trial[J].Clin Lung Cancer, 2015,16(4):262-273.
[7] Schiller J H,Harrington D,Belani C P,et al.Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J].N Engl J Med,2002,346(2):92-98.
[8] Scagliotti G V,Parikh P,von Pawel J,et al.Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551.
[9] Scagliotti G V,Park K,Patil S,et al.Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaive patients with advanced non-small cell lung cancer:a risk-benefit analysis of a large phase III study[J].Eur J Cancer, 2009,45(13):2298-2303.
[10] Paz-Ares L G,de Marinis F,Dediu M,et al.PARAMOUNT:Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer[J].J Clin Oncol,2013,31(23):2895-2902.
[11] Cardenal F,Lopez-Cabrerizo M P,Anton A,et al.Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer[J].J Clin Oncol,1999,17(1):12-18.
[12] Horita H,Law A,Hong S,et al.Identifying regulatory posttranslational modificati-ons of PD-L1:afocus on monoubiquitinaton[J].Neoplasia,2017,19(4):346-353.
[13] Postow M A,Callahan M K,Wolchok J D.Immune checkpoint blockade in cancer therapy[J].J Clin Oncol,2015,33(17):1974-1982.
[14] Yang Y,Wang Z,Fang J,et al.Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nNonsquamous NSCLC:a randomized,double-blind,phase 3 study (oncology program by innovENT anti-PD-1-11) [J].J Thorac Oncol,2020,15(10):1636-1646.
[15] Zhou C,Chen G,Huang Y,et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL):a randomised,open-label,multicentre,phase 3 trial [J].Lancet Respir Med,2021,9(3):305-314.
[16] Zhu C,Xing X X,Wu B,et al.Cost-Effectiveness analysis of camrelizumab plus chemotherapy vs. chemotherapy alone as the first-line treatment in patients with IIIB-IV non-squamous non-small cell lung cancer (NSCLC) without EGFR and ALK alteration from a perspective of health-care system in China[J].Front Pharmacol,2021,12:735536.
[17] Goulart B,Ramsey S.A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer[J].Value Health,2011,14(6):836-845.
[18] Wu B,Chen H,Shen J,et al.Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China[J].Clin Ther,2011,33(10):1446-1455.
[19] 张家豪，张亚杰，李鹤成. 2020年V1版《NCCN非小细胞肺癌临床实践指南》更新解读[J].中国胸心血管外科临床杂志，2020，27（6）：614-618.
[20] 王李婷，彭六保，彭烨，等. 2020年版和2011年版中国药物经济学评价指南比较分析[J].中国药物经济学，2021，16（3）：5-8，15.
[21] Guyot P,Ades A E,Ouwens M J,et al.Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves[J].BMC Med Res Methodol,2012,12:9.
[22] 张天嵩，董圣杰，杨智荣，等.网络Meta分析研究进展系列（十三）：生存数据的网络Meta分析[J].中国循证心血管医学杂志，2021，13（6）：649-652.
[23] Jansen J P.Network meta-analysis of survival data with fractional polynomials[J].BMC Med Res Methodol,2011,11:61.
[24] Rui M,Fei Z,Wang Y,et al.Cost-effectiveness analysis of sintilimab+chemotherapy versus camrelizumab+chemotherapy for the treatment of first-line locally advanced or metastatic nonsquamous NSCLC in China[J].Journal of medical economics,2022,25(1):618-629.
[25] Paz-Ares L,Vicente D,Tafreshi A,et al.A randomized,placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC:protocol-specified final analysis of KEYNOTE-407[J].J Thorac Oncol,2020,15(10):1657-1669.
[26] Chouaid C,Agulnik J,Goker E,et al.Health-related quality of life and utility in patients with advanced non-small-cell lung cancer:a prospective cross-sectional patient survey in a real-world setting[J].J Thorac Oncol,2013,8(8):997-1003.
[27] Nafees B,Lloyd A J,Dewilde S,et al.Health state utilities in non-small cell lung cancer:An international study[J].Asia Pac J Clin Oncol,2017,13(5):e195-e203.
[28] Tolley K,Goad C,Yi Y,et al.Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia[J].Eur J Health Econ,2013,14(5):749-759.
[29] Wan X,Luo X,Tan C,et al.First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic,nonsquamous non-small cell lung cancer:a United States-based cost-effectiveness analysis[J].Cancer,2019,125(20):3526-3534.
[30] Teng M M,Chen S Y,Yang B,et al.Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China[J].Cancer Med,2021,10(18):6344-6353.
[31] Freeman S C,Cooper N J,Sutton A J,et al.Challenges of modelling approaches for network meta-analysis of time-to-event outcomes in the presence of non-proportional hazards to aid decision making:application to a melanoma network[J].Stat Methods Med Res,2022,31(5):839-861.
[32] Wang L,Paller C J,Hong H,et al.Comparison of systemic treatments for metastatic castration-sensitive prostate cancer:asystematic review and network meta-analysis[J].JAMA Oncol,2021,7(3):412-420.
[33] Wang L,Hong H,Alexander G C,et al.Cost-effectiveness of systemic treatments for metastatic castration-sensitive prostate cancer:an economic evaluation based on network meta-analysis[J].Value Health,2022,25(5):796-802.

相似文献/References:

[1]田梦媛,殷 潇,张欲晓,等.吉非替尼治疗晚期非小细胞肺癌的医保预算影响分析[J].卫生经济研究,2016,(12):25.
[2]邱英鹏,肖 月,史黎炜,等.内窥镜手术器械控制系统辅助治疗的成本效果分析[J].卫生经济研究,2018,(06):13.
[3]孙 辉,陈英耀,任绍聪,等.非小细胞肺癌患者疾病治疗偏好与意愿支付研究[J].卫生经济研究,2018,(09):6.
　SUN Hui,CHEN Ying-yao,REN Shao-cong,et al.Study on Disease Treatment Preference and Willingness Payment in Patients with Non-small Cell Lung Cancer[J].Journal Press of Health Economics Research,2018,(2):6.
[4]孙 辉,陈英耀,何露洋,等.医生治疗非小细胞肺癌的选择偏好研究[J].卫生经济研究,2018,(09):10.
　SUN Hui,CHEN Ying-yao,HE Lu-yang,et al.Doctor's Choice Preference for Non-small Cell Lung Cancer Treatment[J].Journal Press of Health Economics Research,2018,(2):10.
[5]隋宾艳,赵 琨.肝细胞癌患者术后辅助CIK细胞免疫治疗的成本效果分析[J].卫生经济研究,2018,(10):6.
　SUI Bin-yan,ZHAO Kun.Cost-effectiveness Analysis of Adjuvant CIK Cell Immunotherapy of Post-operative Patients with Hepatocellular Carcinoma[J].Journal Press of Health Economics Research,2018,(2):6.
[6]丁海樱,孔思思,孙 娇,等.盐酸安罗替尼用于晚期非小细胞肺癌治疗的成本效用分析[J].卫生经济研究,2020,(05):19.
　DING Hai-ying,KONG Si-si,SUN Jiao,et al.Cost-effectiveness Analysis of Anlotinib Hydrochloride for Treatment of Advanced Non-Small Cell Lung Cancer[J].Journal Press of Health Economics Research,2020,(2):19.
[7]李园园,杜灵彬,王悠清,等.浙江省食管癌筛查的经济学评价——以生命年为效果指标[J].卫生经济研究,2022,39(3):18.
　LI Yuan-yuan,DU Ling-bin,WANG You-qing,et al.Economic Evaluation of Esophageal Cancer Screening in Zhejiang Province——Take Life Year as the Effect Index[J].Journal Press of Health Economics Research,2022,39(2):18.
[8]姜 巍,刘亭亭,董亚丽,等.“糖尿病诊疗适宜技术培训”策略的成本效果分析[J].卫生经济研究,2022,39(5):21.
　JIANG Wei,LIU Ting-ting,DONG Ya-li,et al.Cost-Effectiveness Analysis of Training of Appropriate Technologies for Managing Diabetes[J].Journal Press of Health Economics Research,2022,39(2):21.

更新日期/Last Update: 2023-02-01